Mabion S.A. (WSE:MAB)
7.17
-0.03 (-0.42%)
Jun 12, 2026, 5:00 PM CET
Mabion Revenue
Mabion had revenue of 4.57M PLN in the quarter ending March 31, 2026, with 68.30% growth. This brings the company's revenue in the last twelve months to 17.61M, down -53.36% year-over-year. In the year 2025, Mabion had annual revenue of 15.76M, down -77.17%.
Revenue (ttm)
17.61M
Revenue Growth
-53.36%
P/S Ratio
6.58
Revenue / Employee
87.19K
Employees
204
Market Cap
115.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.76M | -53.26M | -77.17% |
| Dec 31, 2024 | 69.02M | -82.66M | -54.50% |
| Dec 31, 2023 | 151.68M | -12.30M | -7.50% |
| Dec 31, 2022 | 163.98M | 127.92M | 354.72% |
| Dec 31, 2021 | 36.06M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIOTON | 266.02M |
| Ryvu Therapeutics | 88.38M |
| Synthaverse | 42.19M |
| Molecure | 6.52M |
| Urteste | 2.50M |
| Captor Therapeutics Spolka Akcyjna | 2.38M |
| Pharmena | 1.61M |
| Poltreg | 250.00K |
Mabion News
- 25 days ago - Mabion Quarterly report: Q1 2026 - Filings
- 25 days ago - Mabion Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Mabion Slides: Q4 2025 - Filings
- 6 weeks ago - Mabion Annual report: Q4 2025 - Filings
- 6 months ago - Mabion Quarterly report: Q3 2025 - Filings
- 9 months ago - Mabion Quarterly report: Q2 2025 - Filings
- 1 year ago - Mabion Quarterly report: Q1 2025 - Filings
- 1 year ago - Mabion Annual report: Q4 2024 - Filings